Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis

Autor: Freiman, JM, Jacobson, KR, Muyindike, WR, Horsburgh, CR, Eller, JJ, Hahn, JA, Linas, BP

Publikováno v: Journal of acquired immune deficiency syndromes (1999), vol 77, iss 4
Freiman, JM; Jacobson, KR; Muyindike, WR; Horsburgh, CR; Eller, JJ; Hahn, JA; et al.(2018). Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 77(4), 405-412. doi: 10.1097/QAI.0000000000001610. UCSF: Retrieved from: http://www.escholarship.org/uc/item/809561tn

BACKGROUND:Isoniazid preventive therapy (IPT) reduces mortality among people living with HIV (PLHIV) and is recommended for those without active tuberculosis (TB) symptoms. Heavy alcohol use, however, is contraindicated for liver toxicity concerns. W

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::6172d1d8c412f567a4b1fd856d61fe9a
https://escholarship.org/uc/item/809561tn

Prevalence of elevated liver transaminases and their relationship with alcohol use in people living with HIV on anti-retroviral therapy in Uganda.

Autor: Freiman JM; Department of Medicine and Section of Infectious Diseases, Boston Medical Center, Boston, MA, United States of America., Fatch R; Department of Medicine, University of California, San Francisco, CA, United States of America., Cheng D; Department of Biostatistics, Boston University School of Public Health, Boston, MA, United States of America., Emenyonu N; Department of Medicine, University of California, San Francisco, CA, United States of America., Ngabirano C; Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda., Geadas C; Department of Medicine and Section of Infectious Diseases, Boston Medical Center, Boston, MA, United States of America., Adong J; Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda., Muyindike WR; Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.; Mbarara Regional Referral Hospital, Mbarara, Uganda., Linas BP; Department of Medicine and Section of Infectious Diseases, Boston Medical Center, Boston, MA, United States of America., Jacobson KR; Department of Medicine and Section of Infectious Diseases, Boston Medical Center, Boston, MA, United States of America., Hahn JA; Department of Medicine, University of California, San Francisco, CA, United States of America.; Department of Epidemiology, University of California, San Francisco, San Francisco, CA, United States of America.

Publikováno v: PloS one [PLoS One] 2021 Jun 01; Vol. 16 (6), pp. e0250368. Date of Electronic Publication: 2021 Jun 01 (Print Publication: 2021).

Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: Analysis of a global dataset.

Autor: Freiman JM; Boston Medical Center, Section of Infectious Diseases, Boston University School of Public Health, Boston, USA. Electronic address: j.morgan.freiman@bmc.org., Wang J; Boston Medical Center, Section of Infectious Diseases, Boston University School of Public Health, Boston, USA., Easterbrook PJ; Global Hepatitis Programme, World Health Organization, Geneva, Switzerland., Horsburgh CR; Department of Biostatistics, Section of Infectious Diseases, Boston University School of Public Health, Boston, USA; Department of Epidemiology, Section of Infectious Diseases, Boston University School of Public Health, Boston, USA; Global Health, Section of Infectious Diseases, Boston University School of Public Health, Boston, USA., Marinucci F; FIND, Geneva, Switzerland., White LF; Department of Biostatistics, Section of Infectious Diseases, Boston University School of Public Health, Boston, USA., Kamkamidze G; Georgia Hepatitis C Elimination Program, Tbilisi, Georgia., Krajden M; British Columbia Centre for Disease Control, Vancouver, Canada., Loarec A; Epicentre, Medecins Sans Frontières, Paris, France., Njouom R; Centre Pasteur of Cameroon, Yaoundé, Cameroon., Nguyen KV; National Hospital of Tropical Diseases, Hanoi, Viet Nam., Shiha G; Department of Internal Medicine, University of Mansoura, Egypt; Egyptian Liver Research Institute and Hospital, Mansoura, Egypt., Soliman R; Egyptian Liver Research Institute and Hospital, Mansoura, Egypt., Solomon SS; YR Gaitonde Centre for AIDS Research and Education, Chennai, India; Johns Hopkins University School of Medicine, Baltimore, USA., Tsertsvadze T; Georgia Hepatitis C Elimination Program, Tbilisi, Georgia., Denkinger CM; FIND, Geneva, Switzerland., Linas B; Boston Medical Center, Section of Infectious Diseases, Boston University School of Public Health, Boston, USA; Department of Epidemiology, Section of Infectious Diseases, Boston University School of Public Health, Boston, USA. Electronic address: Benjamin.linas@bmc.org.

Publikováno v: Journal of hepatology [J Hepatol] 2019 Jul; Vol. 71 (1), pp. 62-70. Date of Electronic Publication: 2019 Feb 21.

Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection: A Systematic Review and Meta-analysis.

Autor: Freiman JM, Tran TM, Schumacher SG, White LF, Ongarello S, Cohn J, Easterbrook PJ, Linas BP, Denkinger CM

Publikováno v: Annals of internal medicine [Ann Intern Med] 2016 Sep 06; Vol. 165 (5), pp. 345-55. Date of Electronic Publication: 2016 Jun 21.

Effect of bilateral vagosympathetic nerve blockade on response of the dog upper esophageal sphincter (UES) to intraesophageal distention and acid.

Autor: Freiman JM, El-Sharkawy TY, Diamant NE

Publikováno v: Gastroenterology [Gastroenterology] 1981 Jul; Vol. 81 (1), pp. 78-84.